IN2014DN10404A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10404A
IN2014DN10404A IN10404DEN2014A IN2014DN10404A IN 2014DN10404 A IN2014DN10404 A IN 2014DN10404A IN 10404DEN2014 A IN10404DEN2014 A IN 10404DEN2014A IN 2014DN10404 A IN2014DN10404 A IN 2014DN10404A
Authority
IN
India
Prior art keywords
pde7
addictions
phosphodiesterase
directed
disclosure
Prior art date
Application number
Other languages
English (en)
Inventor
Gregory A Demopulos
George A Gaitanaris
Roberto Ciccocioppo
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/835,607 external-priority patent/US9220715B2/en
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of IN2014DN10404A publication Critical patent/IN2014DN10404A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Addiction (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN10404DEN2014 2012-05-07 2013-05-07 IN2014DN10404A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643611P 2012-05-07 2012-05-07
US13/835,607 US9220715B2 (en) 2010-11-08 2013-03-15 Treatment of addiction and impulse-control disorders using PDE7 inhibitors
PCT/US2013/039866 WO2013176877A2 (en) 2012-05-07 2013-05-07 Treatment of addiction and impulse-control disorders using pde7 inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN10404A true IN2014DN10404A (pt) 2015-08-14

Family

ID=49624481

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10404DEN2014 IN2014DN10404A (pt) 2012-05-07 2013-05-07

Country Status (10)

Country Link
EP (1) EP2846805B1 (pt)
JP (1) JP2015521177A (pt)
CN (3) CN104768556A (pt)
AU (1) AU2013266793B2 (pt)
CA (1) CA2871151C (pt)
IN (1) IN2014DN10404A (pt)
PL (1) PL2846805T3 (pt)
RS (1) RS58381B1 (pt)
SI (1) SI2846805T1 (pt)
WO (1) WO2013176877A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2817071C (en) 2010-11-08 2018-04-24 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
RU2019108464A (ru) * 2016-08-26 2020-09-28 Мицубиси Танабе Фарма Корпорейшн Бициклическое азотсодержащее гетероциклическое соединение
WO2023243659A1 (ja) * 2022-06-15 2023-12-21 真一 松本 線条体ストリオソームのドパミンｄ１シグナルを標的とした強迫性障害の薬物療法
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2437755T3 (es) * 2004-07-01 2014-01-14 Daiichi Sankyo Company, Limited Intermedios para derivados de tienopirazol que tienen actividad inhibitoria de PDE 7
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
JP5411504B2 (ja) * 2005-09-26 2014-02-12 メディシノバ， インコーポレイテッド 薬物嗜癖および行動嗜癖を治療するためのイブジラストの使用
US20080260643A1 (en) * 2007-03-27 2008-10-23 Omeros Corporation Use of pde7 inhibitors for the treatment of movement disorders
US8637528B2 (en) * 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
EP3053440B1 (en) * 2007-04-11 2020-08-12 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
FR2943673B1 (fr) * 2009-03-27 2013-03-29 Sanofi Aventis Applications therapeutiques de derives de quinazolinedione
FR2944282B1 (fr) * 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
CA2817071C (en) * 2010-11-08 2018-04-24 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors

Also Published As

Publication number Publication date
CN112168972A (zh) 2021-01-05
EP2846805A2 (en) 2015-03-18
EP2846805B1 (en) 2018-11-21
WO2013176877A2 (en) 2013-11-28
EP2846805A4 (en) 2016-08-10
AU2013266793B2 (en) 2016-08-04
PL2846805T3 (pl) 2019-05-31
SI2846805T1 (sl) 2019-04-30
RS58381B1 (sr) 2019-04-30
AU2013266793A1 (en) 2014-11-27
CN104768556A (zh) 2015-07-08
CN114984229A (zh) 2022-09-02
CA2871151C (en) 2019-03-26
JP2015521177A (ja) 2015-07-27
WO2013176877A3 (en) 2015-06-18
CA2871151A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
EP4275752A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
HK1205938A1 (en) Inhibitors of human ezh2, and methods of use thereof ezh2
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
EP2836270A4 (en) SYSTEMS AND METHODS RELATED TO THE TREATMENT OF BACK PAIN
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
PH12015502302B1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
IN2014CN04014A (pt)
IN2014DN10404A (pt)
PL2780025T3 (pl) Zastosowanie ekstraktów z wiązówki (Filipendula) do leczenia i profilaktyki przewlekłych stanów bólowych
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2014004991A (es) Combinaciones terapeuticas y metodos para tratar el melanoma.
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
MX2014014839A (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.
MX2016005614A (es) Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
HK1223014A1 (zh) 用於在預防和/或治療多動性運動障礙中使用的治療劑
EP2710017A4 (en) MACROCYCLIC THERAPEUTIC AGENTS AND METHODS OF TREATMENT
HRP20181746T1 (hr) Trpc4 modulatori za uporabu u liječenju ili prevenciji bola
CO7151515A2 (es) Métodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis múltiple que utilizan una aminopiridina
WO2012097121A9 (en) Specific nnos inhibitors for the therapy and prevention of human melanoma
HRP20190279T1 (hr) Liječenje ovisnosti i poremećaja nagona pomoću pde7 inhibitora
HK1209073A1 (en) Plod-2 stimulators and their use in the treatment of skin plod-2
AU2013101402A4 (en) Timber treatment formulations and methods of use
MX2013006527A (es) Derivados de arilsulfonamida para la prevencion o el tratamiento de los trastornos oftalmologicos especificos.